Valneva has updated the Serious Adverse Events and the Warnings and Precaution sections of the prescribing information for the Chikungunya vaccine Ixchiq to include a warning about its use among people over the age of 60 with multiple underlying health conditions.

Ixchiq is indicated to prevent Chikungunya virus (CHIKV) in people 18 years of age and older who are at high risk of exposure to the virus. It contains a live, weakened version of the chikungunya virus and may cause symptoms similar to those of chikungunya disease. Chikungunya virus is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes. It can cause fever, severe joint and muscle pain, headache, nausea, fatigue and rash. The joint pain is often debilitating and can persist for weeks to years.

Regu

See Full Page